Skip to main content
Publications
Djibo DA, Margulis AV, McMahill-Walraven CN, Saltus C, Shuminski P, Kaye JA, Johannes C, Caligaert B, Libertin M, Graham S. Performance of endometrial cancer case finding algorithms among women with select comorbidities in US claims data. Poster presented at the 2022 North American Menopause Society Meeting; October 13, 2022. Atlanta, GA.
Hoffman V, Hallas J, Linder M, Margulis A, Suehs BT, Arana A, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD. Cardiovascular risk in users of mirabegron relative to users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, real-world data safety study. Poster presented at the 2020 Virtual American Heart Association’s Scientific Sessions; November 13, 2020.
de Vogel S, Hoffman V, Phiri K, Seeger J, Arana A, Margulis A, McQuay L, Perez-Gutthann S, Hallas J, Sahlertz Kristiansen N, Suehs B, Uribe C, Appenteng K, Robinson NJ. The Mirabegron Post-marketing Requirements (PMRs)/ Non-interventional Post-authorization Safety Study (NI-PASS) Program. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Njue A, Margulis AV, Lyall M, Nuabor W, Marks M, Russell K, Sinha A. Congenital cytomegalovirus: what are the rates of maternal screening, diagnostic amniocentesis, and elective termination? Poster presented at the ID Week 2019; October 4, 2019. Washington, DC.
Margulis A, Andrews E, Hernandez-Diaz S, Magyari M, Rivero-Ferrer E, Bader-Weder S, Evershed J, Garas M, Wang Q, Wormser D. Design of a multi-source post-marketing study to evaluate pregnancy and infant outcomes in women with multiple sclerosis who were exposed to ocrelizumab during, or within 6 months before, pregnancy. Poster presented at the 2018 American Academy of Neurology Annual Meeting; April 25, 2018. Los Angeles, CA.